한글목차

전 세계 원시 치료 시장 규모는 2024년 34억 2,736만 달러에서 2033년에는 66억 5,186만 달러에 달할 것으로 예상되며, 2025-2033년 예측 기간 동안 7.5%의 CAGR로 성장할 것으로 예상됩니다.

주요 요약

원시는 어린이와 성인 모두에게 널리 나타나는 굴절 질환으로 향후 합병증을 예방하기 위해 정기적인 평가와 치료가 필요합니다. 성인의 원시는 특정 문제와 관련이 있기 때문에 정기적인 평가가 필요합니다. 이 활동에서는 장기적인 예방을 위한 원시의 평가와 관리에 대해 알아봅니다.

시장 역학:

촉진요인과 억제요인

원시 유병률 증가

원시 치료 시장을 이끄는 주요 요인 중 하나는 특히 노인층에서 원시 유병률의 증가입니다. 노안과 원시는 눈의 수정체가 자연적으로 노화되면서 발생하는 증상으로, 나이가 들어감에 따라 인접한 물체에 초점을 맞추는 능력이 저하됩니다.

예를 들어, 병적 원시는 생리적 원시(단순 원시 및 기능적 원시)보다 훨씬 적습니다. 축 길이의 감소가 원시를 유발하는 경우가 가장 많습니다. 미국의 원시 유병률은 약 10%로 약 1,400만 명에 해당합니다. 경도의 원시는 만삭 신생아의 대다수가 앓고 있는 증상입니다. 생후 6-9개월까지 약 4-9%의 유아가 원시가 되며, 생후 12개월까지 약 3.6%의 유병률을 보입니다.

따라서 원시의 유병률이 특히 노년층에서 증가함에 따라 안경, 콘택트렌즈, 굴절교정수술과 같은 교정 수단에 대한 수요가 증가하고 있으며, 미국 인구의 약 10%가 영향을 받고 있다는 점을 감안할 때 효과적인 치료법의 필요성은 앞으로 더욱 커질 것으로 보입니다.

치료 후 합병증 및 부작용 위험

원시 치료 시장은 라식, PRK, 렌즈삽입술과 같은 수술적 개입으로 인한 치료 후 합병증 및 부작용의 위험으로 인한 도전에 직면해 있습니다. 이러한 위험은 안구건조증, 눈부심, 눈부심, 후광, 시력저하와 같은 부작용으로 이어져 비용과 회복 시간을 증가시킵니다. 이로 인해 환자들은 고급 원시 치료를 고려하는 동기를 잃게 되고, 도입이 제한되어 시장 성장에 영향을 미칩니다.

예를 들어, NCBI의 최근 연구에 따르면, 교정 렌즈는 원시를 효과적으로 관리할 수 있지만, 수술적 치료는 부작용이 있을 수 있기 때문에 신중한 환자 선택과 상담이 필요합니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 원시 증가
    • 눈의 생체 역학에 기반한 맞춤형 레이저 수술 증가
  • 성장 억제요인
    • 치료 후 합병증 및 부작용 리스크
    • 치료 시술의 높은 비용
  • 기회
    • 신흥 시장에 대한 진출
  • 영향 분석

제5장 전략적 인사이트와 업계 전망

• 시장 리더와 선구자
  • 새로운 선구자와 저명 기업
  • 최대 매출을 자랑하는 브랜드를 확립한 리더
  • 확립된 제품을 보유한 시장 리더
• CXO의 견해
• 최신 개발과 혁신
• 사례 연구/진행중인 연구
• 규제와 상환 상황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• Porter's Five Forces 분석
• 파이프라인 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 수요와 격차
• 시장 진출 및 확장을 위한 추천 전략
• 시나리오 분석 베스트 케이스, 기본 케이스, 워스트 케이스 예측
• 가격 분석과 가격 시장 역학
• KOL(Key Opinion Leader)

제6장 유형별

• 축성 원시
• 곡률 원시
• 굴절률 원시
• 위치 원시

제7장 치료 유형별

• 안경·콘택트렌즈
• 굴절교정 수술

제8장 연령층별

• 소아
• 성인
• 노인

제9장 최종사용자별

• 병원
• 안과 클리닉과 아이케어 센터
• 외래 수술 센터(ASC)
• 소매점 및 온라인 안경점

제10장 지역별

• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제11장 경쟁 구도

• 경쟁 시나리오
• 시장 상황·점유율 분석
• M&A 분석

제12장 기업 개요

• Zeimer Ophthalmic Systems AG
  • 기업 개요
  • 제품 포트폴리오
    • 제품 설명
    • 제품의 주요 실적평가 지표(KPI)
    • 실적 및 예측 제품 판매
    • 제품 판매량
  • 재무 개요
    • 기업 매출
    • 지역별 수익 분배
    • 매출 예측
  • 주요 발전
    • 인수합병
    • 주요 제품 개발 활동
    • 규제 당국 승인등
  • SWOT 분석
• Carl Zeiss Meditec AG
• ALCON Inc
• Bausch Health Companies Inc.
• Johnson & Johnson Vision
• NIDEK CO. LTD
• Essilor Luxottica(Essilor Ltd)
• The Cooper Companies Inc
• Ophtec
• Staar Surgical
• SCHWIND eye-tech-solutions GmbH
  • 파이프라인 제품 설명
  • 제품의 주요 실적평가 지표(KPI)
  • 주요 활동
  • 시장 진출 타임라인
  • 제품 보급률
  • 매출 추정과 예측
• ORA, Inc
• Cloudbreak Therapeutics

제12장 부록

영문목차

The global hyperopia treatment market reached US$ 3,427.36 million in 2024 and is expected to reach US$ 6,651.86 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

Executive Summary

Hyperopia, a prevalent refractive condition in both children and adults, requires regular assessment and treatment to prevent future complications. Adult hyperopia is linked to certain issues, necessitating regular assessment. This activity reviews hyperopia evaluation and management for long-term prevention.

Market Dynamics: Drivers & Restraints

Growing Prevalence of Hyperopia

One of the primary factors driving the hyperopia treatment market is the increasing prevalence of hyperopia, particularly among the elderly population. Presbyopia and hyperopia are conditions that result from the natural deterioration of the eye's lens, which impairs the ability of individuals to focus on adjacent objects as they age.

For instance, pathologic hyperopia is considerably less prevalent than physiologic (Simple and Functional) hyperopia. A reduction in axial length most frequently causes hyperopia. The United States has an overall prevalence of hyperopia of approximately 10%, translating to approximately 14 million individuals. Mild hyperopia is a condition that affects the majority of full-term neonates. Approximately 4-9% of infants are hyperopic by the age of 6-9 months, and the prevalence is approximately 3.6% by the age of 12 months.

Hence, the increasing prevalence of hyperopia, particularly among the elderly, which drives demand for corrective solutions like eyeglasses, contact lenses, and refractive surgeries with around 10% of the U.S. population affected, the need for effective treatment options continues to grow.

Risk of Post-Treatment Complications and Side Effects

The hyperopia treatment market faces challenges due to the risk of post-treatment complications and side effects from surgical interventions like LASIK, PRK, and lens implantation. These risks can lead to adverse effects like dry eyes, glare, halos and vision regression, increasing the cost and recovery time. This discourages patients from considering advanced hyperopia treatments, limiting their adoption and impacting market growth.

For instance, according to NCBI recent studies indicate that corrective lenses effectively manage hyperopia, but surgical treatments require careful patient selection and counseling due to potential side effects.

Segment Analysis

The global hyperopia treatment market is segmented based on type, treatment type, age group, end user and region.

Treatment Type:

Eye Glasses & Contact Lenses in the treatment type segment is expected to dominate the hyperopia treatment with the highest market share

Hyperopia can be corrected using aspheric high-index lenses or spherical lenses, depending on the strength of the prescription. High-index lenses are thinner and lighter, with a slimmer profile. Anti-reflective coatings are recommended for glasses. Spherical lenses can also correct hyperopia. Wearing options include daily disposable and weekly or monthly contact lenses. Eye Glasses and contact lens prescriptions for farsightedness usually start with plus numbers. Both lenses are suitable for higher prescriptions and offer a slimmer profile.

For instance, Johnson & Johnson Vision Care has approved ACUVUE Theravision with Ketotifen, an etafilcon A drug-eluting contact lens with ketotifen. The FDA-approved lenses contain 19 mcg of ketotifen, an established antihistamine. This marks the first in a new category of contact lenses for those with allergic eye itch, offering a new wearing experience.

Moreover, both contact lenses and eyeglasses contribute to the correction of refractive errors by altering the manner in which light is reflected and bent into the retina. Typically, eyeglasses that correct for farsightedness are larger in the midsection because they are often correcting for a "plus prescription" and a cornea that is too flat. If the prescription is substantial, this may result in a magnified or "bug eye" appearance.

Geographical Analysis

North America is expected to hold a significant position in the hyperopia treatment market with highest market share

North America holds a substantial position in the hyperopia treatment market and is expected to hold most of the market share owing to FDA approvals, advanced healthcare infrastructure, advanced technologies and rising awareness. The aging population, ophthalmic device manufacturers, and favorable reimbursement policies contribute to market growth. The surge in customized procedures and premium intraocular lenses strengthens the market.

For instance, in January 2025, the U.S. FDA approved the excimer laser MEL 90 from Zeiss Meditech for myopia, hyperopia and mixed astigmatism. The laser integrates into Zeiss' Corneal Refractive Workflow, complementing Visumax 800 and SMILE pro software, ensuring efficient surgical correction with positive outcomes.

Hence, the FDA has approved the Zeiss Meditech MEL 90 excimer laser, boosting the hyperopia treatment market by expanding surgical options, improving procedural efficiency, and precision, thus driving innovation and adoption of laser-based hyperopia treatments.

Competitive Landscape

The major global players in the hyperopia treatment market include Zeimer Ophthalmic Systems AG, Carl Zeiss Meditec AG, ALCON Inc, Bausch Health Companies Inc, Johnson & Johnson Vision, NIDEK CO. LTD, Essilor Luxottica (Essilor Ltd), the Cooper Companies Inc, Ophtec, Staar Surgical and among others.

Key Developments

• In August 2024, ZEISS Medical Technology unveiled its latest cataract and corneal refractive workflow innovations at the European Society of Cataract and Refractive Surgeons (ESCRS) conference. The company is the first to offer hyperopia treatment with lenticule extraction using SMILE pro in CE markets. ZEISS also celebrates surpassing the 10 million marks for lenticule extraction procedures with ZEISS SMILE and ZEISS SMILE pro. The company will introduce advanced optical and digital ophthalmic microscopes and showcase its enhanced IOL portfolio.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

The global hyperopia treatment market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Age Group
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing Prevalence of Hyperopia
    • 4.1.1.2. Rise in Customized Laser Surgery Based on Eye Biomechanics
  • 4.1.2. Restraints
    • 4.1.2.1. Risk of Post-Treatment Complications and Side Effects
    • 4.1.2.2. High Cost of Treatment Procedures
  • 4.1.3. Opportunity
    • 4.1.3.1. Expansion into Emerging Markets
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Pipeline Analysis
• 5.8. Supply Chain Analysis
• 5.9. Patent Analysis
• 5.10. SWOT Analysis
• 5.11. Unmet Needs and Gaps
• 5.12. Recommended Strategies for Market Entry and Expansion
• 5.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.14. Pricing Analysis and Price Dynamics
• 5.15. Key Opinion Leaders

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Axial Hyperopia*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Curvature Hyperopia
• 6.4. Index Hyperopia
• 6.5. Positional Hyperopia

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Eye Glasses & Contact Lenses*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Refractive Surgery

8. By Age Group

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 8.1.2. Market Attractiveness Index, By Age Group
• 8.2. Pediatric*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Adults
• 8.4. Geriatric

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Ophthalmic Clinics & Eye Care Centers
• 9.4. Ambulatory Surgical Centers (ASCs)
• 9.5. Retail & Online Optical Stores

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. Latin America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Mexico
    • 10.4.7.2. Brazil
    • 10.4.7.3. Argentina
    • 10.4.7.4. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

• 12.1. Zeimer Ophthalmic Systems AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. Carl Zeiss Meditec AG
• 12.3. ALCON Inc
• 12.4. Bausch Health Companies Inc.
• 12.5. Johnson & Johnson Vision
• 12.6. NIDEK CO. LTD
• 12.7. Essilor Luxottica (Essilor Ltd)
• 12.8. The Cooper Companies Inc
• 12.9. Ophtec
• 12.10. Staar Surgical
• Similar data will be provided for each market player.

Emerging Market Players

• 12.11. SCHWIND eye-tech-solutions GmbH*
  • 12.11.1. Pipeline Products Description
  • 12.11.2. Product Key Performance Indicators (KPIs)
  • 12.11.3. Key Activities
  • 12.11.4. Market Entry Timelines
  • 12.11.5. Product Penetration Rate
  • 12.11.6. Sales Estimation and Projections
• 12.12. ORA, Inc
• 12.13. Cloudbreak Therapeutics
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1 About Us and Services
• 12.2 Contact Us